SCHEMBL22983771

SCHEMBL22983771

O=[N+]([O-])c1cc2c(Nc3cc(Cl)ccc3F)ncnc2cc1OS(=O)(=O)C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 0.48
FLT1 P17948 3/20 0.48
FGFR1 P11362 2/20 0.48
FLT4 P35916 2/20 0.48
EPHB2 P29323 1/20 0.48
EGFR P00533 9/20 0.47
ABCG2 Q9UNQ0 1/20 0.46
RET P07949 1/20 0.43
KIF5B P33176 1/20 0.43
EPHA2 P29317 2/20 0.42
EPHB4 P54760 2/20 0.42
SRC P12931 1/20 0.42
FBP1 P09467 1/20 0.42
ERBB2 P04626 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31472862 1.00 KDR (0.48) KDRFLT1FGFR1FLT4EPHB2
SCHEMBL28797709 0.89 KDR (0.45) KDRFLT1FGFR1FLT4EPHB2
SCHEMBL29924080 0.86 EGFR (0.50) KDRFLT1EPHB2EGFRABCG2
SCHEMBL29718969 0.86 EGFR (0.50) EGFRABCG2
SCHEMBL29924017 0.86 EGFR (0.50) EGFRABCG2
SCHEMBL22983661 0.86 EGFR (0.50) KDRFLT1EPHB2EGFRABCG2
SCHEMBL29719083 0.86 EGFR (0.50) KDRFLT1EPHB2EGFRABCG2
SCHEMBL22983644 0.86 EGFR (0.50) EGFRABCG2
SCHEMBL22983424 0.82 KDR (0.50) KDRFLT1FGFR1FLT4EPHB2
SCHEMBL31472883 0.82 KDR (0.50) KDRFLT1FGFR1FLT4EPHB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4013749-B1 ALKYNYL QUINAZOLINE COMPOUNDS BLACK DIAMOND THERAPEUTICS INC (US) 2026-03-11 EP disclosed
US-20260049063-A1 ALKYNYL QUINAZOLINE COMPOUNDS BLACK DIAMOND THERAPEUTICS INC (US) 2026-02-19 US disclosed
US-12435046-B2 Alkynyl quinazoline compounds BLACK DIAMOND THERAPEUTICS, INC. (US) 2025-10-07 US disclosed
US-20220298120-A1 ALKYNYL QUINAZOLINE COMPOUNDS BLACK DIAMOND THERAPEUTICS, INC. 2022-09-22 US disclosed
CN-114787150-A Alkynyl quinazoline compounds 黑钻治疗公司 2022-07-22 CN disclosed
EP-4013749-A1 ALKYNYL QUINAZOLINE COMPOUNDS Black Diamond Therapeutics, Inc. (US) 2022-06-22 EP disclosed
WO-2021030711-A1 ALKYNYL QUINAZOLINE COMPOUNDS BLACK DIAMOND THERAPEUTICS, INC. (US) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435046-B2 Alkynyl quinazoline compounds GLS, GLS2, MCL1 KDR 917/4885FLT1 1932/4885FGFR1 242/4885
US-20220298120-A1 ALKYNYL QUINAZOLINE COMPOUNDS GLS, GLS2, MCL1 KDR 917/4885FLT1 1932/4885FGFR1 242/4885
US-20260049063-A1 ALKYNYL QUINAZOLINE COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, BCL6 KDR 1101/4885FLT1 1508/4885FGFR1 213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.